Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

BHV-2100

Other · developed by Biohaven

Phase 2 Most advanced trial (none active)
BHVN Developer
1 Registered trials

What is BHV-2100?

BHV-2100 is an investigational drug studied in Migraine.

At a glance

Drug type
Other
Therapy area
Neurology
Developer
Biohaven (BHVN)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06603623 Phase 2 Migraine Completed BHVN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Migraine

More from Biohaven

BHV-1300 Phase 3 BHV-1400 Phase 3 BHV-1530 Phase 1 BHV-700 Phase 1 BHV-7000 Phase 2/3 BHV-8000 Phase 2/3 PBI-410 Phase 1/2 Talditercept Alfa Phase 3 Troriluzole Phase 3 Verdiperstat Phase 3

Follow BHVN, the company behind BHV-2100

See BHVN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

BHVN catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.